MAPT and Alzheimer disease: In APP/PS1 double-transgenic AD mice XX mice, downregulation of CCR3 rescued symptoms of AD, manifested by decreased amyloid beta production, tau hyperphosphorylation, neuroinflammation, ameliorated dendritic synaptic loss, and rescued impairments in spatial learning and memory [1298].